Grail (NASDAQ: GRAL)
$13.55
(1.7%)
$0.23
Price as of September 12, 2024, 4:00 p.m. ET
Grail Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Grail Company Info
Grail develops a pan-cancer screening test designed to detect cancers at an early stage. Its pan-cancer screening test measures circulating nucleic acids in blood using high-intensity sequencing, population-scale clinical trials, enabling doctors to develop blood tests for early-stage cancer detection. The company was founded in 2016 by Alex Aravanis and Jeff Huber in Menlo Park, California.
News & Analysis
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.